v3.26.1
Stock-Based Payments (Tables)
 3 Months Ended
Jul. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
July 31,
20262025
General and administrative$271 $148 
Sales and marketing44 12 
Research and development439 32 
Cost of oncology revenue12 16 
Total stock-based compensation expense$766 $208 
Schedule of Valuation Assumptions For Stock Options
Black-Scholes and Monte Carlo assumptions used to calculate the fair value of Champions options granted by the Company during the three months ended July 31, 2026 and 2025 were as follows:
Three Months Ended
July 31,
20262025
Expected term in years
6
6
Risk-free interest rates
4.32%
4.08% - 4.50%
Volatility
53.30%
55.65% - 62.00%
Dividend yield—%—%
Black-Scholes assumptions used to calculate the fair value of Corellia options granted by Corellia during the three months ended July 31, 2026 and 2025 were as follows:

Three Months Ended
July 31,
20262025
Expected term in years66
Risk-free interest rates4.09%4.15%
Volatility65%65%
Dividend yield—%—%
Schedule of Stock Option Activity
The Company’s stock options activity for the 2021 and 2010 equity incentive plans for the three months ended July 31, 2026 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20262,632,320 7,500 2,639,820 $5.84 6.4$2,673,000 
Granted62,500 — 62,500 5.78 9.96 years
Exercised(31,743)— (31,743)2.69 
Forfeited— — — — 
Canceled(57,137)— (57,137)6.58 
Expired— — — — 
Outstanding, July 31, 20262,605,940 7,500 2,613,440 $5.86 6.4$1,970,000 
Vested and expected to vest as of July 31, 20262,605,940 7,500 2,613,440 $5.86 6.4$1,970,000 
Exercisable as of July 31, 20261,480,794 7,500 1,488,294 $5.00 4.4$1,967,000 
    
The stock options activity for the Corellia 2023 Global equity incentive plan for the three months ended July 31, 2026 was as follows:
Directors
and
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 2026300 300 $1,682.00 9.06$110,000 
Granted250 250 2,047.00 9.80
Outstanding, July 31, 2026550 550 $1,847.91 9.26$325,000 
Vested and expected to vest as of July 31, 2026550 550 $1,847.91 9.26$325,000 
Exercisable as of July 31, 2026400 400 $1,910.13 9.43$212,000